BioNTech SE

NasdaqGS:BNTX 주식 보고서

시가총액: US$20.4b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BioNTech 대차 대조표 상태

재무 상태 기준 확인 5/6

BioNTech 의 총 주주 지분은 €20.0B 이고 총 부채는 €2.3M, 이는 부채 대 자기자본 비율을 0.01% 로 가져옵니다. 총자산과 총부채는 각각 €22.3B 및 €2.3B 입니다.

주요 정보

0.01%

부채 비율

€2.30m

부채

이자 보상 비율n/a
현금€15.67b
주식€19.97b
총 부채€2.29b
총 자산€22.26b

최근 재무 상태 업데이트

Recent updates

Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

Jun 16
Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

Jun 13

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

May 11
Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

May 08
Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

BioNTech Earnings Preview: I Will Stay On The Sidelines

May 03

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Apr 22
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Mar 27
We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 24
BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09
BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18
Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

Jan 02
Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Dec 11
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

Oct 22
Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Sep 11
BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Jun 13
Is BioNTech (NASDAQ:BNTX) A Risky Investment?

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

May 23
A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Mar 29
BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

Mar 05
These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Feb 18
A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

Feb 02
Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

Jan 26
With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

Nov 19
BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

Nov 09
BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

CDC advisory panel recommends COVID vaccines for children be included in federal program

Oct 19

Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?

Oct 18
Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?

Hong Kong approves BioNTech COVID vaccine for infants

Oct 12

EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids

Oct 03

재무 상태 분석

단기부채: BNTX 의 단기 자산 ( €18.3B )이 단기 부채( €1.6B ).

장기 부채: BNTX 의 단기 자산( €18.3B )이 장기 부채( €682.6M ).


부채 대 자본 내역 및 분석

부채 수준: BNTX 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: BNTX 의 부채 대 자기자본 비율은 지난 5년간 21.1% 에서 0.01% 로 감소했습니다.

부채 범위: BNTX 의 부채는 영업 현금 흐름 ( 249195.7% )에 의해 잘 충당되었습니다.

이자 보장: BNTX 의 부채에 대한 이자 지급EBIT에 의해 잘 충당되었는지 판단할 데이터가 부족합니다.


대차 대조표


건강한 기업 발견하기